The cJun N-terminal kinase (JNK) signaling pathway has been extensively studied with regard to its involvement in neurodegenerative processes, but little is known about its functions in neurotransmission. In a mouse model of Parkinson's disease (PD), we show that the pharmacological activation of dopamine D1 receptors (D1R) produces a large increase in JNK phosphorylation. This effect is secondary to dopamine depletion, and is restricted to the striatal projection neurons that innervate directly the output structures of the basal ganglia (dSPN). Activation of JNK in dSPN relies on cAMP-induced phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), but does not require N-methyl-D-aspartate (NMDA) receptor transmission. Electrophysiological experiments on acute brain slices from PD mice show that inhibition of JNK signaling in dSPN prevents the increase in synaptic strength caused by activation of D1Rs. Together, our findings show that dopamine depletion confers to JNK the ability to mediate dopamine transmission, informing the future development of therapies for PD.
Introduction
Dopamine transmission is involved in numerous basic physiological processes and its abnormal activity is characteristic of several neuropsychiatric and neurodegenerative disorders, including drug addiction and Parkinson's disease (PD). Dopamine's effects are enacted through binding to two major types of G-protein coupled receptors, the D1 (D1R) and D2 (D2R) receptors, which are linked to stimulation and inhibition of cAMP signaling, respectively (Kebabian and Calne, 1979) .
In experimental models of PD, the loss of dopaminergic afferents to the striatum is associated with sensitized dopamine transmission. Previous work shows that this sensitization is particularly prominent for D1Rs (Aubert et al., 2005; Feyder et al., 2011) , which are selectively expressed in the striatal projection neurons (SPNs) that form the direct pathway to the output nuclei of the basal ganglia (Gerfen et al., 1990) . D1R sensitization in response to dopamine depletion has been attributed to abnormal recruitment of D1Rs at the cell surface, as well as increased levels of G olf and adenylyl cyclase (Berthet et al., 2009; Corvol et al., 2004; Guigoni et al., 2007; Rangel-Barajas et al., 2011) . These changes dramatically enhance the effects produced by dopaminergic drugs on cAMP signaling (Santini et al., 2007) . In addition, sensitized D1R transmission confers on L-DOPA, the most commonly prescribed medication for PD, the ability to activate non-canonical signal transduction pathways, such as the extracellular signal-regulated kinases (ERK) and the mammalian target of rapamycin (Santini et al., 2007; Gerfen et al., 2002; Pavon et al., 2006; Santini et al., 2009; Westin et al., 2007; Santini et al., 2010) . Whether activation of sensitized D1Rs also leads to the stimulation of other downstream targets in SPNs remains to be established.
The cJun N-terminal kinase (JNK) signaling pathway is a member of the mitogen-activated protein kinase family, which has been extensively studied with regard to cell survival and proliferation. The primary target of JNK is the early response transcription factor, cJun, which is a component of the activator protein-1 (AP-1) (Coffey, 2014; Manning and Davis, 2003) . JNK-mediated phosphorylation enhances the transcriptional efficiency of cJun by increasing its binding to DNA at promoter sites (Derijard et al., 1994; Papavassiliou et al., 1995) . Work in human neuroblastoma cells showed that D1Rs activate JNK via stimulation of cAMP-dependent protein kinase (Zhen et al., 1998) . Moreover, repeated administration of cocaine, a drug which acts by promoting dopamine transmission, results in a transient increase in the phosphorylation of JNK (Go et al., 2010) . However, despite the potential clinical implications, very little is known on the role of JNK in dopamine transmission in PD.
